LMAT LEMAITRE VASCULAR INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1158895 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.8%
TTM net income YoY18.7%
TTM EPS YoY18.5%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR32.4%
Margins
Gross margin72.0%
Operating margin27.7%
Net margin23.5%
FCF margin24.9%
EBITDA margin31.7%
Returns
ROE15.6%
ROA10.1%
ROIC (approx.)15.3%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio14.60x
Interest coverage14.35x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio-2.1%
Payout ratio34.2%
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $67.97M | $70.38M | $66.55M | $64.45M | $61.05M | $64.23M | $59.87M | $55.72M |
| Cost of revenue | $19.27M | $19.62M | $18.16M | $18.26M | $15.09M | $19.26M | $18.45M | $17.13M |
| Gross profit | $48.70M | $50.76M | $48.40M | $46.19M | $45.95M | $44.97M | $41.42M | $38.59M |
| R&D expense | $4.42M | $4.85M | $4.06M | $3.53M | $2.97M | $3.54M | $4.09M | $3.62M |
| SG&A expense | $12.08M | $11.11M | $12.05M | $10.39M | $10.75M | $10.40M | $10.49M | $9.49M |
| Operating income | $17.70M | $20.40M | $17.77M | $18.83M | $20.31M | $16.14M | $12.63M | $12.85M |
| Interest expense | $1.30M | $1.30M | $1.30M | $1.30M | $1.30M | $1.30M | $1.29M | $205,000 |
| Pretax income | $19.67M | $22.19M | $19.67M | $20.30M | $22.57M | $18.07M | $14.24M | $14.02M |
| Income tax | $4.65M | $5.14M | $3.99M | $4.72M | $5.21M | $4.29M | $3.23M | $2.84M |
| Net income | $15.02M | $17.05M | $15.68M | $15.58M | $17.36M | $13.78M | $11.01M | $11.18M |
| EBITDA | $20.58M | $23.06M | $20.40M | $21.44M | $22.93M | $18.79M | $15.18M | $15.33M |
| EPS (basic) | 0.66 | 0.75 | 0.69 | — | 0.77 | 0.61 | 0.49 | — |
| EPS (diluted) | 0.65 | 0.74 | 0.68 | — | 0.75 | 0.60 | 0.48 | — |
| Dividends declared per share | 0.25 | 0.25 | 0.25 | 0.20 | 0.20 | 0.20 | 0.20 | 0.16 |
| Weighted avg. shares (diluted) | 23.07M | 24.53M | 23.03M | — | 24.39M | 22.89M | 22.90M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $27.49M | $26.62M | $26.85M | $28.24M | $25.49M | $27.18M | $25.34M | $25.61M |
| Short-term investments | $362.23M | $349.62M | $340.38M | $330.88M | $317.56M | $292.31M | $277.21M | $274.11M |
| Receivables | $35.88M | $35.68M | $35.77M | $33.61M | $32.42M | $36.54M | $35.11M | $30.06M |
| Current assets | $505.51M | $488.30M | $477.82M | $468.23M | $452.02M | $430.13M | $408.11M | $402.19M |
| PP&E, net | $30.46M | $29.59M | $28.54M | $27.00M | $26.46M | $25.36M | $25.11M | $24.80M |
| Goodwill | $65.94M | $65.94M | $65.94M | $65.94M | $65.94M | $65.94M | $65.94M | $65.94M |
| Intangibles | $29.30M | $30.54M | $31.67M | $33.09M | $31.71M | $33.15M | $34.40M | $35.82M |
| Total assets | $656.03M | $640.55M | $629.53M | $615.69M | $598.07M | $577.59M | $556.01M | $551.82M |
| Current liabilities | $34.62M | $29.93M | $33.37M | $36.32M | $33.29M | $30.82M | $24.75M | $30.61M |
| Total liabilities | $223.90M | $220.21M | $222.90M | $222.17M | $219.15M | $214.91M | $208.43M | $214.53M |
| Shareholders' equity | $432.13M | $420.34M | $406.62M | $393.52M | $378.92M | $362.69M | $347.57M | $337.29M |
| Shares outstanding | 22.88M | 22.86M | 22.85M | 22.77M | — | — | — | 22.55M |
| Cash flow statement | ||||||||
| Operating cash flow | $21.99M | $15.96M | $15.09M | $23.16M | $28.76M | $20.29M | $9.04M | $15.18M |
| Capital expenditure | $2.33M | $2.31M | $2.78M | $1.78M | $2.28M | $1.34M | $1.38M | $2.04M |
| Free cash flow | $19.66M | $13.65M | $12.31M | $21.38M | $26.48M | $18.95M | $7.66M | $13.14M |
| Investing cash flow | -$16.21M | -$11.08M | -$13.12M | -$16.82M | -$27.45M | -$16.35M | -$4.32M | -$173.89M |
| Financing cash flow | -$4.97M | -$5.05M | -$3.22M | -$3.59M | -$2.95M | -$2.76M | -$5.24M | $164.08M |
| Depreciation & amortization | $2.88M | $2.66M | $2.62M | $2.60M | $2.61M | $2.65M | $2.55M | $2.48M |
| Stock-based compensation | $2.03M | $1.94M | $2.09M | $2.10M | $1.74M | $1.94M | $2.05M | $1.74M |
| Dividends paid | $5.72M | $5.72M | $5.71M | $4.54M | $4.54M | $4.52M | $4.52M | $3.60M |
| Share buybacks | $0 | $17,000 | $460,000 | $1.22M | $0 | $4,000 | $601,000 | $1.35M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.